A Locke Lord team led by Chris Graham and Nicole Chakraborty (both of Providence) represented MindImmune Therapeutics, Inc., in the issuance and sale of $12.4 million Series A convertible preferred stock. Based in Kingston, Rhode Island, MindImmune is a drug discovery company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, such as Alzheimer’s disease and other neuropsychiatric disorders. Locke Lord has advised MindImmune Therapeutics since 2016 in a variety of corporate matters and prior series of convertible notes and stock offerings. For more information, see the press release. Additional assistance was provided by Ted Augustinos (Hartford), Lori Basilico (Providence), Peter Wynacht (Chicago), Barry Bendes (New York) and Ralph Loren (Boston).
Posted on June 13, 2022